for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck & Co., Inc.

MRK.N

Latest Trade

76.61USD

Change

0.91(+1.20%)

Volume

4,167,568

Today's Range

76.19

 - 

77.55

52 Week Range

71.72

 - 

87.79

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
75.70
Open
76.28
Volume
4,167,568
3M AVG Volume
259.61
Today's High
77.55
Today's Low
76.19
52 Week High
87.79
52 Week Low
71.72
Shares Out (MIL)
2,532.06
Market Cap (MIL)
191,043.80
Forward P/E
12.35
Dividend (Yield %)
3.45

Next Event

Dividend For TCXMRK.CHA - 0.6500 USD

Latest Developments

More

Linnaeus Therapeutics Announced Expansion Of Ongoing Clinical Collaboration With Merck

Merck Announces Supply Agreement With U.S. Government For Molnupiravir, An Investigational Oral Antiviral Candidate For Treatment Of Mild To Moderate Covid-19

Lynparza Reduces Risk Of Invasive Disease Recurrence Or Death In Patients With Early Breast Cancer In Phase 3 Trial

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merck & Co., Inc.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.

Industry

Biotechnology & Drugs

Contact Info

2000 Galloping Hill Rd

KENILWORTH, NJ

07033-1310

United States

+1.908.7404000

http://www.merck.com/

Executive Leadership

Kenneth C. Frazier

Chairman of the Board, Chief Executive Officer

Robert M. Davis

President

Caroline Litchfield

Chief Financial Officer, Executive Vice President

Franklin K. Clyburn

President, Human Health, Head of Human Health Commercial and Marketing

Dean Y. Li

President - Merck Research Laboratories

Key Stats

2.08 mean rating - 26 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

42.3K

2019

46.8K

2020

48.0K

2021(E)

48.4K
EPS (USD)

2018

4.340

2019

5.190

2020

5.940

2021(E)

6.109
Price To Earnings (TTM)
27.28
Price To Sales (TTM)
3.98
Price To Book (MRQ)
7.09
Price To Cash Flow (TTM)
17.72
Total Debt To Equity (MRQ)
115.99
LT Debt To Equity (MRQ)
89.08
Return on Investment (TTM)
11.21
Return on Equity (TTM)
8.02

Latest News

Latest News

U.S. signs $1.2 billion deal for 1.7 million courses of Merck's experimental COVID-19 drug

Merck & Co Inc said on Wednesday the U.S. government has agreed to pay about $1.2 billion for 1.7 million courses of its experimental COVID-19 treatment, if it is proven to work in an ongoing large trial and authorized by U.S. regulators.

Merck says U.S. govt to buy about 1.7 mln courses of co's COVID-19 drug

Merck & Co Inc said on Wednesday the U.S. government has agreed to buy about 1.7 million courses of the company's experimental COVID-19 drug, molnupiravir, for about $1.2 billion, if it is authorized in the country. (Reporting by Manojna Maddipatla in Bengaluru; Editing...

AstraZeneca's Lynparza reduces relapse, death in breast cancer patients

AstraZeneca Plc's drug Lynparza reduced the risk of relapse and death in breast cancer patients with certain mutations in a late-stage trial, the British drugmaker said on Thursday.

Germany's Merck sees boost from labs supplies earnings

Germany's Merck on Wednesday said its Life Science business, a leading maker of biotech lab supplies and gear, saw core earnings jump more than 43% in the first quarter, driven by the pharma industry's efforts to fight the coronavirus pandemic.

German labs supplier Merck raises forecast on strong first quarter

German biotech labs supplier Merck raised its 2021 earnings forecast on strong first-quarter results, as efforts by the pharma industry to ready treatments and vaccines against the coronavirus bolsters demand for its products.

Congo declares end of Ebola outbreak that killed six

The Democratic Republic of Congo on Monday declared the end of an Ebola outbreak that infected 12 people in the eastern province of North Kivu and killed six of them.

Congo declares end of Ebola outbreak that killed six

The Democratic Republic of Congo on Monday declared the end of an Ebola outbreak that infected 12 people in the eastern province of North Kivu and killed six of them.

U.S. drugmaker Merck sees bigger hit to full-year sales from pandemic

Merck & Co Inc said on Thursday it would take a bigger hit to sales this year than previously expected due to a resurgence in COVID-19 cases that has hurt demand for drugs that need to be given by doctors.

BRIEF-Merck Says Not Extending Trial For COVID-19 Drug Molnupiravir Into India At This Time

* MERCK & CO EXEC SAYS Q1 VACCINE SALES HURT BY RECOMMENDATIONS AGAINST CO-ADMINISTRATION OF COVID-19 VACCINES WITH OTHER SHOTS

Merck quarterly profit falls on COVID-19 hit

Merck & Co Inc reported a 1% fall in quarterly profit on Thursday, hurt by a drop in visits to the doctor's office because of a resurgence in COVID-19 cases at the beginning of the year in the United States. (Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila...

Merck taps five Indian drugmakers to expand COVID-19 drug production

Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.

Merck taps 5 Indian drugmakers to expand COVID-19 drug production

Merck & Co Inc said on Tuesday it had tied up with five generic drugmakers in India to expand access to molnupiravir, an experimental antiviral COVID-19 therapy it is developing with Ridgeback Biotherapeutics. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Ramakrishnan...

Merck plans large outpatient trial of COVID-19 pill, stops study in hospitalized patients

Merck & Co Inc on Thursday said it plans a large study of what could become the first pill to target the coronavirus in people at risk of severe COVID-19, but will no longer pursue use of the experimental antiviral drug in hospitalized patients.

WHO joins Europe, Merck in recommending against ivermectin for COVID-19

The World Health Organization (WHO) on Wednesday recommended against using generic anti-parasite drug ivermectin in patients with COVID-19 except for clinical trials, because of a lack of data demonstrating its benefits.

Merck names Caroline Litchfield as new CFO

Merck & Co Inc said on Wednesday Caroline Litchfield will succeed Robert Davis as the company's chief financial officer from April 1.

UPDATE 1-EU regulator warns against use of Merck's anti-parasite drug for COVID-19

Europe's drugs regulator on Monday warned against the use of Merck & Co's anti-parasite drug, ivermectin, for the treatment or prevention of COVID-19 outside clinical trials.

EU regulator advises against use of Merck's anti-parasite drug for COVID-19

The European medicines regulator on Monday advised against the use of Merck & Co's anti-parasite drug, ivermectin, for the treatment or prevention of COVID-19 outside clinical trials.

Merck's marketing executive Michael Nally to step down

Merck & Co said on Wednesday its Chief Marketing Officer Michael Nally will leave the company, the second top executive to do so after the drugmaker announced last month its Chief Executive Officer Kenneth Frazier will step down in June.

Gilead, Merck collaborate to develop long-acting HIV treatment

Gilead Sciences Inc and rival Merck & Co Inc said on Monday they will test a combination of their experimental HIV drugs to develop a long-acting treatment for the infection that affects millions worldwide.

Gilead, Merck collaborate to develop HIV treatment - WSJ

Drug makers Gilead Sciences Inc and Merck & Co Inc are collaborating to develop a long-acting HIV therapy, the Wall Street Journal reported on Monday. (Reporting By Mrinalika Roy in Bengaluru; Editing by Shounak Dasgupta)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up